Evidence map›Paper›PMID 41063290›Full record

ReviewStem cell research & therapy2025

Mesenchymal stromal cell-mediated mitochondrial transfer unveils new frontiers in disease therapy.

Huan Chen, Xu Chen, Zi-Hao Zhou, Jia-Rong Zheng, Ye Lu, Pei Lin, Yun-Fan Lin, Yu-Cheng Zheng, Bin Xiong, Rong-Wei Xu and 2 more

Abstract readReview
In one paragraph

Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Huan Chen *School of Stomatology, Stomatological Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China.
Xu Chen *School of Stomatology, Stomatological Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China.
Zi-Hao Zhou *School of Stomatology, Stomatological Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China.
Jia-Rong ZhengDepartment of Dentistry, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China.
Ye LuSchool of Stomatology, Stomatological Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China.
Pei LinSchool of Stomatology, Stomatological Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China.
Yun-Fan LinSchool of Stomatology, Stomatological Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China.
Yu-Cheng ZhengSchool of Stomatology, Stomatological Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China.
Bin XiongSchool of Stomatology, Stomatological Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China.
Rong-Wei XuSchool of Stomatology, Stomatological Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China.
Li CuiSchool of Stomatology, Stomatological Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China. licui@smu.edu.cn.ORCID http://orcid.org/0000-0001-9814-6945
Xin-Yuan ZhaoSchool of Stomatology, Stomatological Hospital, Southern Medical University, Guangzhou, 510280, Guangdong, China. zhaoxinyuan1989@smu.edu.cn.

Funding

Guangdong Provincial Science and Technology Project Foundation 2022A0505050038Science Research Cultivation Program of Stomatological Hospital, Southern Medical University PY2020002Science Research Cultivation Program of Stomatological Hospital, Southern Medical UniversityScience Research Cultivation Program of Stomatological Hospital, Southern Medical University PY2022019the National Natural Science Foundation of China 81901006the National Natural Science Foundation of China 82372905Young Top-notch Talent of Pearl River Talent Plan 0920220228
6 · The paper itself

Abstract

Mitochondrial dysfunction is a pivotal factor in the progression of various diseases, making it a critical therapeutic target. Mesenchymal stromal cells (MSCs) have shown promise in mitigating this dysfunction through the transfer of healthy mitochondria to damaged cells. This review comprehensively analyzes the mechanisms of MSC-derived mitochondrial transfer, including tunneling nanotubes (TNTs) and extracellular vesicles, and highlights their therapeutic potential across a spectrum of diseases, such as neurodegenerative disorders, ocular diseases, and inflammatory conditions. Additionally, strategies to enhance mitochondrial transfer efficiency-such as genetic modifications and optimization of MSC sources-are thoroughly explored. Despite these promising findings, challenges remain, including the need for a deeper understanding of transfer mechanisms, ensuring the quality and functionality of transferred mitochondria, and addressing potential immune responses. While MSC-derived mitochondrial transfer holds significant therapeutic potential, careful consideration of its dual nature, especially in specific pathological contexts such as cancer, is essential. With further research and technological advancements, this approach could become a cornerstone in the treatment of diseases characterized by mitochondrial dysfunction.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationMitochondriaNeurodegenerative DiseasesAnimalsExtracellular VesiclesHumansMesenchymal stromal cellMitochondrial transferTherapeutic efficacy

Identifiers

PMID41063290
PMCPMC12505854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.